[
  {
    "ts": "2026-01-20T11:00:00+00:00",
    "headline": "Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection",
    "summary": "At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; [95% CI, 0.294-0.887]) compared to KEYTRUDA alone ...",
    "url": "https://finance.yahoo.com/news/moderna-merck-announce-5-data-110000479.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "449ac09a-53b1-3b8e-bd31-18eb9785f02a",
      "content": {
        "id": "449ac09a-53b1-3b8e-bd31-18eb9785f02a",
        "contentType": "STORY",
        "title": "Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection",
        "description": "",
        "summary": "At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; [95% CI, 0.294-0.887]) compared to KEYTRUDA alone ...",
        "pubDate": "2026-01-20T11:00:00Z",
        "displayTime": "2026-01-20T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "<![CDATA[At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination ...]]>",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y14NrymWnVHtLPxT5mPm5g--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dSewxxG3XkMHQTa3gmVr6w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-merck-announce-5-data-110000479.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-merck-announce-5-data-110000479.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-20T11:58:00+00:00",
    "headline": "Moderna, Merck Report Positive Results From Cancer-Vaccine Study",
    "summary": "Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.",
    "url": "https://www.wsj.com/health/pharma/moderna-merck-report-positive-results-from-cancer-vaccine-study-73fb3b5f?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "6346d102-e3b9-3805-a961-d2f396d717de",
      "content": {
        "id": "6346d102-e3b9-3805-a961-d2f396d717de",
        "contentType": "STORY",
        "title": "Moderna, Merck Report Positive Results From Cancer-Vaccine Study",
        "description": "",
        "summary": "Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.",
        "pubDate": "2026-01-20T11:58:00Z",
        "displayTime": "2026-01-20T11:58:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/6346d102-e3b9-3805-a961-d2f396d717de/moderna-merck-report.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/edba716920a958d03ad5887cab7b4720",
          "originalWidth": 1279,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mCq3YC7Yav9XgZM.i5eFtw--~B/aD02NDA7dz0xMjc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/edba716920a958d03ad5887cab7b4720.cf.webp",
              "width": 1279,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6kv6Fn8S6q.9tiHo_iNa7Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/edba716920a958d03ad5887cab7b4720.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/moderna-merck-report-positive-results-from-cancer-vaccine-study-73fb3b5f?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-20T23:07:14+00:00",
    "headline": "Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer",
    "summary": "On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.",
    "url": "https://www.fool.com/coverage/stock-market-today/2026/01/20/stock-market-today-jan-20-immunitybio-soars-again-after-fda-outlines-resubmission-path-for-anktiva-in-bladder-cancer/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "d0e25dd3-e4a1-3835-a50e-110032a6f9f9",
      "content": {
        "id": "d0e25dd3-e4a1-3835-a50e-110032a6f9f9",
        "contentType": "STORY",
        "title": "Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer",
        "description": "",
        "summary": "On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.",
        "pubDate": "2026-01-20T23:07:14Z",
        "displayTime": "2026-01-20T23:07:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/ece2644f62c999828edb4a744e8a56b7",
          "originalWidth": 1401,
          "originalHeight": 1251,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NgY1Ki3DIZazmtFGOnbBXw--~B/aD0xMjUxO3c9MTQwMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/ece2644f62c999828edb4a744e8a56b7.cf.webp",
              "width": 1401,
              "height": 1251,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0zzA8_T8EPIY32gZoC6R8w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/ece2644f62c999828edb4a744e8a56b7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/stock-market-today/2026/01/20/stock-market-today-jan-20-immunitybio-soars-again-after-fda-outlines-resubmission-path-for-anktiva-in-bladder-cancer/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stock-market-today-jan-20-230714765.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IBRX"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "NVAX"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]